KLP Kapitalforvaltning AS Purchases 7,300 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

KLP Kapitalforvaltning AS lifted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 366,359 shares of the company’s stock after purchasing an additional 7,300 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Teva Pharmaceutical Industries were worth $6,140,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in Teva Pharmaceutical Industries by 804.7% during the first quarter. GAMMA Investing LLC now owns 67,474 shares of the company’s stock worth $1,037,000 after acquiring an additional 60,016 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Teva Pharmaceutical Industries by 0.8% during the 1st quarter. Rhumbline Advisers now owns 281,062 shares of the company’s stock valued at $4,320,000 after purchasing an additional 2,128 shares in the last quarter. Yousif Capital Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 1.9% during the 1st quarter. Yousif Capital Management LLC now owns 55,986 shares of the company’s stock valued at $861,000 after purchasing an additional 1,033 shares in the last quarter. Handelsbanken Fonder AB bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at about $243,000. Finally, Zhang Financial LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 13.2% during the 1st quarter. Zhang Financial LLC now owns 17,200 shares of the company’s stock valued at $264,000 after purchasing an additional 2,000 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider owned 6,774 shares in the company, valued at $102,693.84. This represents a 47.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Eric A. Hughes sold 52,742 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. Company insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $20.01 on Friday. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The firm has a market capitalization of $22.95 billion, a PE ratio of -125.04, a PEG ratio of 1.16 and a beta of 0.71. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The business’s 50-day simple moving average is $18.51 and its 200 day simple moving average is $16.95.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm’s revenue for the quarter was up .3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TEVA has been the topic of a number of research reports. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Friday, October 3rd. Finally, UBS Group boosted their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $25.57.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.